Nippon Boehringer Ingelheim Co Ltd.
Industry / private company
Location:
Kobe,
Japan (JP)
ISNI: 0000000446781308
ROR: https://ror.org/02r1d7x68
Show on Map:
Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, with Cytochrome P450 and P-Glycoprotein Substrates: Findings from in Vitro Analyses and an Open-Label, Single-Sequence Phase i Study (2023)
Desch M, Schlecker C, Hohl K, Liesenfeld KH, Chan T, Müller F, Wunderlich G, et al.
Journal article
Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation (2020)
Marton A, Kaneko T, Kovalik JP, Yasui A, Nishiyama A, Kitada K, Titze J
Journal article, Review article
Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine (2020)
Wiebe ST, Giessmann T, Hohl K, Schmidt-Gerets S, Hauel E, Jambrecina A, Bader K, et al.
Journal article
A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Drug–Drug–Gene Interaction Model of Metformin and Cimetidine in Healthy Adults and Renally Impaired Individuals (2020)
Hanke N, Türk D, Selzer D, Ishiguro N, Ebner T, Wiebe S, Müller F, et al.
Journal article
Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions (2018)
Stopfer P, Giessmann T, Hohl K, Hutzel S, Schmidt S, Gansser D, Ishiguro N, et al.
Journal article